<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>PromptGenix – Commercialization</title>
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="description" content="PromptGenix commercialization plan: customers, value, competition, business model, milestones, and go-to-market."/>
  <style>
    *{ box-sizing:border-box; }
    body{
      margin:0;
      font-family:-apple-system,BlinkMacSystemFont,"Segoe UI",sans-serif;
      background:#020617;
      color:#e5e7eb;
      line-height:1.5;
    }
    a{ color:inherit; text-decoration:none; }
    .page{ min-height:100vh; display:flex; flex-direction:column; }

    header{
      position:sticky; top:0; z-index:30;
      backdrop-filter: blur(14px);
      background: rgba(15, 23, 42, 0.92);
      border-bottom: 1px solid rgba(148, 163, 184, 0.3);
    }
    .nav{
      max-width:1120px; margin:0 auto; padding:14px 20px;
      display:flex; align-items:center; justify-content:space-between; gap:18px;
    }
    .nav-left{ display:flex; align-items:center; gap:12px; }
    .logo-dot{
      width:28px; height:28px; border-radius:999px;
      background: radial-gradient(circle at 0 0,#38bdf8,#8b5cf6);
      box-shadow:0 0 18px rgba(56,189,248,.7);
    }
    .brand{ font-size:1.1rem; font-weight:650; letter-spacing:.04em; }
    .subbrand{ font-size:.72rem; color:#9ca3af; margin-top:2px; }

    .nav-links{ display:flex; gap:10px; flex-wrap:wrap; justify-content:flex-end; }
    .nav-links a{
      font-size:.88rem; color:#9ca3af;
      padding:6px 10px; border-radius:999px;
      border:1px solid rgba(148,163,184,0.18);
      background: rgba(2,6,23,0.25);
    }
    .nav-links a:hover{
      color:#e5e7eb;
      background: rgba(148,163,184,0.18);
      border-color: rgba(148,163,184,0.35);
    }
    .nav-links a.active{
      color:#e5e7eb;
      background: rgba(148,163,184,0.18);
      border-color: rgba(148,163,184,0.55);
    }

    main{ flex:1; }
    .section{
      max-width:1120px;
      margin:0 auto;
      padding:28px 20px;
    }

    .topline{
      display:flex; flex-wrap:wrap; gap:10px;
      align-items:flex-end; justify-content:space-between;
      padding-top: 16px;
      margin-bottom: 14px;
    }
    .doc-title{
      font-size: 1.35rem;
      font-weight: 820;
      color:#f9fafb;
      margin: 0;
    }
    .meta{
      font-size:.78rem;
      color:#9ca3af;
    }

    .kicker{
      font-size:.78rem;
      text-transform:uppercase;
      letter-spacing:.18em;
      color:#a5b4fc;
      margin-bottom:6px;
    }
    h2{
      font-size:1.12rem;
      font-weight:760;
      color:#f9fafb;
      margin:14px 0 8px;
    }
    p{
      margin:0 0 10px;
      font-size:.93rem;
      color:#d1d5db;
    }

    .grid-2{
      display:grid;
      grid-template-columns: minmax(0,1.05fr) minmax(0,1fr);
      gap:18px;
      align-items:start;
      margin-top:10px;
    }

    .card{
      border-radius:16px;
      padding:14px 16px;
      background: rgba(15,23,42,0.84);
      border: 1px solid rgba(148,163,184,0.28);
      box-shadow: 0 18px 45px rgba(15,23,42,0.55);
    }
    .card h3{
      margin:0 0 8px;
      font-size:.95rem;
      letter-spacing:.14em;
      text-transform:uppercase;
      color:#a5b4fc;
    }

    ul{
      margin:6px 0 0;
      padding-left:1.1rem;
      color:#d1d5db;
      font-size:.92rem;
    }
    li{ margin-bottom:6px; }
    li strong{ color:#e5e7eb; }

    .pill-row{ display:flex; flex-wrap:wrap; gap:8px; margin-top:10px; }
    .pill{
      font-size:.72rem;
      padding:5px 9px;
      border-radius:999px;
      border:1px solid rgba(129,140,248,0.45);
      background: rgba(2,6,23,0.25);
      color:#c7d2fe;
    }

    .callout{
      border-radius:14px;
      padding:12px 14px;
      border:1px dashed rgba(148,163,184,0.5);
      background: rgba(15,23,42,0.75);
      font-size:.88rem;
      color:#e5e7eb;
      margin-top:12px;
    }
    .callout strong{ color:#22c55e; }

    .table{
      width:100%;
      border-collapse: collapse;
      margin-top:10px;
      border-radius:14px;
      overflow:hidden;
      border:1px solid rgba(148,163,184,0.28);
      background: rgba(15,23,42,0.6);
    }
    .table th, .table td{
      padding:10px 10px;
      border-bottom:1px solid rgba(148,163,184,0.18);
      vertical-align:top;
      font-size:.88rem;
      color:#d1d5db;
    }
    .table th{
      font-size:.78rem;
      text-transform:uppercase;
      letter-spacing:.14em;
      color:#a5b4fc;
      background: rgba(2,6,23,0.35);
    }

    footer{
      border-top:1px solid rgba(31,41,55,0.9);
      padding:16px;
      font-size:.78rem;
      color:#6b7280;
      text-align:center;
    }

    @media (max-width: 920px){
      .grid-2{ grid-template-columns: minmax(0,1fr); }
    }

    /* Print friendliness */
    @media print {
      header, footer { display: none !important; }
      .page, main, body { min-height: auto !important; height: auto !important; }
      main { flex: none !important; }

      body { background:#fff !important; color:#111 !important; }
      p, li { color:#111 !important; }
      h1, h2, h3 { color:#111 !important; }
      a { color:#111 !important; text-decoration: none !important; }
      * { box-shadow: none !important; }

      @page { size: Letter; margin: 0.5in; }
      body { font-size: 95%; line-height: 1.32; }

      table, thead, tbody, tr, td, th,
      .grid-2, .card, .callout {
        break-inside: auto !important;
        page-break-inside: auto !important;
      }
      h2, h3 { break-after: avoid-page; page-break-after: avoid; }
      p, li { orphans: 2; widows: 2; }

      .section { max-width: 100% !important; padding: 0 !important; margin: 0 0 0.18in 0 !important; }
      .topline { padding-top: 0 !important; margin-bottom: 0.12in !important; }
      .card { padding: 10px 12px !important; }
      .table th, .table td { padding: 7px 8px !important; }
    }
  </style>
</head>

<body>
<div class="page">
  <header>
    <div class="nav">
      <div class="nav-left">
        <div class="logo-dot"></div>
        <div>
          <div class="brand">PromptGenix</div>
          <div class="subbrand">SBIR Portal</div>
        </div>
      </div>

      <nav class="nav-links">
        <a href="index.html">Portal</a>
        <a href="sbir.html">SBIR</a>
        <a href="aims.html">Aims</a>
        <a href="approach.html">Approach</a>
        <a href="commercialization.html" class="active">Commercialization</a>
        <a href="facilities.html">Facilities</a>
        <a href="team.html">Team</a>
        <a href="use-cases.html">Use Cases</a>
      </nav>
    </div>
  </header>

  <main>
    <section class="section">
      <div class="topline">
        <h1 class="doc-title">Commercialization Plan (Phase I → Phase II)</h1>
        <div class="meta">
          PromptGenix LLC &middot; Contact: dohoon.kim1@icloud.com &middot; promptgenix.org
        </div>
      </div>

      <div class="kicker">Positioning</div>
      <h2>Evidence-weighted hypothesis intelligence engine for faster, more transparent scientific decisions.</h2>
      <p>
        PromptGenix commercializes a <strong>hypothesis intelligence platform</strong> that integrates public biomedical datasets and scientific
        literature to produce <strong>ranked, testable hypotheses with probabilistic confidence</strong>, explicit evidence links, and
        actionable next-step recommendations. The platform is designed to <strong>support</strong> (not replace) human scientific judgment by
        making evidence integration faster, reproducible, and reviewer-friendly.
      </p>
      <div class="callout">
        <strong>Commercial focus:</strong> sell the decision product (ranked hypotheses + uncertainty + traceability), not “data analysis as a service.”
      </div>

      <div class="grid-2">
        <div class="card">
          <h3>Primary customers</h3>
          <ul>
            <li><strong>NIH-funded academic labs</strong> in immunology, infectious disease, vaccine/HIV research</li>
            <li><strong>Government research groups</strong> needing reproducible, auditable decision support (secure/on-prem options)</li>
            <li><strong>Biotech & translational teams</strong> prioritizing targets, biomarkers, and experiments under time constraints</li>
            <li><strong>CROs & core facilities</strong> supporting multiple projects with standardized, traceable deliverables</li>
          </ul>
          <div class="pill-row">
            <span class="pill">Academic</span>
            <span class="pill">Government</span>
            <span class="pill">Biotech</span>
            <span class="pill">CRO / Core</span>
          </div>
        </div>

        <div class="card">
          <h3>Value proposition</h3>
          <ul>
            <li><strong>Faster hypothesis-to-experiment:</strong> compress synthesis from weeks to days (or &lt;24h for accession-driven runs)</li>
            <li><strong>Confidence with uncertainty:</strong> probabilistic ranking + credible intervals and evidence coverage</li>
            <li><strong>Traceability:</strong> every hypothesis links to evidence objects and cited sources (supporting vs. conflicting)</li>
            <li><strong>Reproducibility:</strong> versioned configs, deterministic reruns, exportable artifacts</li>
            <li><strong>Flexible deployment:</strong> local workstation, secure VPC, or on-prem for sensitive settings</li>
          </ul>
        </div>
      </div>

      <div class="kicker" style="margin-top:18px;">Competitive landscape</div>
      <h2>Differentiation vs. point tools, workflow frameworks, and general-purpose AI assistants.</h2>

      <table class="table" aria-label="Competitive differentiation table">
        <thead>
          <tr>
            <th style="width:28%;">Category</th>
            <th style="width:36%;">Strengths</th>
            <th style="width:36%;">PromptGenix differentiation</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td><strong>Point tools</strong><br/>Seurat, GSEA, FlowJo, etc.</td>
            <td>Best-in-class for specific steps; familiar to labs.</td>
            <td>
              Converts outputs into <strong>standardized evidence objects</strong> and produces <strong>ranked hypotheses</strong> with uncertainty,
              reducing manual synthesis and “glue code” across tools.
            </td>
          </tr>
          <tr>
            <td><strong>Workflow scripting</strong><br/>custom pipelines / notebooks</td>
            <td>Flexible; tailored to a lab’s preferences.</td>
            <td>
              Productized, maintainable engine with deterministic configs and reusable templates; easier onboarding and consistent QA/traceability.
            </td>
          </tr>
          <tr>
            <td><strong>Generic LLM assistants</strong></td>
            <td>Fast writing/summarization; broad coverage.</td>
            <td>
              Evidence-weighted inference + “no evidence, no claim” guardrails; LLM used for explanation only, constrained by evidence links,
              citations, and uncertainty flags.
            </td>
          </tr>
        </tbody>
      </table>

      <div class="kicker" style="margin-top:18px;">Business model</div>
      <h2>Subscription-first, with deployment tiers for security and scale.</h2>

      <div class="grid-2">
        <div class="card">
          <h3>Initial go-to-market</h3>
          <ul>
            <li><strong>Pilot program:</strong> 2–3 partner labs (Phase I) with structured KPIs (traceability, usefulness, reproducibility)</li>
            <li><strong>Letters of support:</strong> pilot partners and collaborating PIs to demonstrate Phase II readiness</li>
            <li><strong>Proof assets:</strong> public demo reports + reproducible runs using public datasets and clear “confidence outputs”</li>
            <li><strong>Early channel:</strong> NIH-funded networks, core facilities, and government groups needing auditable decision support</li>
          </ul>
          <div class="callout">
            <strong>Near-term traction:</strong> pilots → references → paid evaluations → Phase II scale-out.
          </div>
        </div>

        <div class="card">
          <h3>Revenue options</h3>
          <ul>
            <li><strong>Subscription (SaaS):</strong> per seat / per lab for hypothesis engine + updates + templates</li>
            <li><strong>Secure tier:</strong> customer VPC / on-prem deployment package (government, regulated biotech)</li>
            <li><strong>Compute add-on:</strong> managed runs for heavy workloads (optional)</li>
            <li><strong>Services:</strong> onboarding, workflow mapping, and support (non-recurring, accelerates adoption)</li>
            <li><strong>Enterprise:</strong> multi-team deployments, SSO, audit logging, and expanded governance</li>
          </ul>
          <div class="pill-row">
            <span class="pill">SaaS</span>
            <span class="pill">Secure tier</span>
            <span class="pill">Hybrid</span>
            <span class="pill">Enterprise</span>
          </div>
        </div>
      </div>

      <div class="kicker" style="margin-top:18px;">Milestones</div>
      <h2>Phase I proves decision value; Phase II scales adoption and revenue.</h2>

      <table class="table" aria-label="Commercialization milestones table">
        <thead>
          <tr>
            <th style="width:22%;">Stage</th>
            <th style="width:48%;">Deliverables</th>
            <th style="width:30%;">Commercial outcome</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td><strong>Phase I</strong></td>
            <td>
              Evidence layer + hypothesis decision engine; traceable reports with confidence bands; pilot KPI evaluation; initial packaging for
              deterministic reruns and audit-friendly artifacts.
            </td>
            <td>
              Demonstrable decision support value; priceable product scope; partner references and Phase II-ready roadmap.
            </td>
          </tr>
          <tr>
            <td><strong>Phase II</strong></td>
            <td>
              Expanded modality coverage and dataset breadth; improved UI and automation; multi-site pilots; governance and secure deployments;
              repeatable onboarding and support workflows.
            </td>
            <td>
              Paid subscriptions and secure deployments; repeatable customer acquisition; scalable revenue and partnerships.
            </td>
          </tr>
        </tbody>
      </table>

      <div class="callout">
        <strong>Commercial thesis:</strong> Customers adopt PromptGenix when it demonstrably reduces hypothesis generation time,
        improves transparency and reproducibility, and produces confidence-ranked hypotheses that directly inform study design decisions.
      </div>

      <p>
        Phase I establishes technical feasibility and reviewer trust using public datasets; Phase II will scale PromptGenix to additional disease areas,
        expand decision-engine calibration, and convert pilot partnerships into revenue through subscription and secure deployment tiers.
      </p>

    </section>
  </main>

  <footer>
    PromptGenix &middot; SBIR Portal &middot;
    <a href="mailto:dohoon.kim1@icloud.com">dohoon.kim1@icloud.com</a>
  </footer>
</div>
</body>
</html>
